Plain-English translation of NCT04824950 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is studying whether a special blood test can detect tumor DNA—tiny fragments of cancer cells circulating in your bloodstream—to better predict how well standard chemotherapy is working. Researchers believe this blood test might be more helpful than current imaging scans at spotting patients whose cancer is not responding well to treatment early on, so doctors can adjust care plans sooner.
Doctors need better ways to tell which patients with this type of chest lymphoma will respond well to chemotherapy and which won't—especially because standard imaging tests can sometimes be misleading. This blood test approach could help identify problems much earlier and allow for more personalized treatment decisions.
You likely qualify if…
You likely don't qualify if…
You would give blood samples at specific timepoints during and after your standard chemotherapy treatment—typically after 2 cycles and 4 cycles of chemotherapy, and possibly at other visits. These blood samples would be tested using advanced sequencing technology to look for traces of tumor DNA. This is an observational study, meaning researchers are monitoring and collecting information; you would continue your regular cancer treatment as planned by your doctor, and the blood draws would happen alongside your normal clinic visits.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
France
Sponsor
Centre Henri Becquerel
Enrollment target
~87 participants
Started
March 2021
Primary completion
March 2028
Age range
18 Years and older
Last updated on clinicaltrials.gov in April 2021.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
VINCENT CAMUS, MD
Centre Henri Becquerel
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.